The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Ann Med. 2023;55(2):2287193. doi: 10.1080/07853890.2023.2287193. Epub 2023 Nov 29.
() is frequently employed in the treatment of ankylosing spondylitis (AS). However, the primary constituents, drug targets, and mechanisms of action remain unidentified.
In this study, various public databases and online tools were employed to gather information on the compounds of , drug targets, and disease targets associated with ankylosing spondylitis. The intersection of drug targets and disease targets was then determined to identify the common targets, which were subsequently used to construct a protein-protein interaction (PPI) network using the STRING database. Network analysis and the analysis of hub genes and major compounds were conducted using Cytoscape software. Furthermore, the Metascape platform was utilized for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. Molecular docking studies and immunohistochemical experiments were performed to validate the core targets.
The network analysis identified 2-Methoxycinnamaldehyde, cinnamaldehyde, and 2-Hydroxycinnamaldehyde as the major effective compounds present in . The PPI network analysis revealed PTGS2, MMP9, and TLR4 as the most highly correlated targets. GO and KEGG analyses indicated that exerts its therapeutic effects in ankylosing spondylitis through various biological processes, including the response to hormones and peptides, oxidative stress response, and inflammatory response. The main signaling pathways involved were IL-17, TNF, NF-kappa B, and Toll-like receptor pathways. Molecular docking analysis confirmed the strong affinity between the key compounds and the core targets. Additionally, immunohistochemical analysis demonstrated an up-regulation of PTGS2, MMP9, and TLR4 levels in ankylosing spondylitis.
This study provides insights into the effective compounds, core targets, and potential mechanisms of action of in the treatment of ankylosing spondylitis. These findings establish a solid groundwork for future fundamental research in this field.
姜黄素经常用于治疗强直性脊柱炎（AS）。然而，其主要成分、药物靶点和作用机制仍不清楚。
本研究采用各种公共数据库和在线工具收集姜黄素的化合物、药物靶点和与强直性脊柱炎相关的疾病靶点信息。然后确定药物靶点和疾病靶点的交集，以鉴定共同靶点，随后使用 STRING 数据库构建蛋白质-蛋白质相互作用（PPI）网络。使用 Cytoscape 软件进行网络分析和关键基因和主要化合物的分析。此外，利用 Metascape 平台进行基因本体论（GO）和京都基因与基因组百科全书（KEGG）分析。进行分子对接研究和免疫组织化学实验以验证核心靶点。
网络分析确定 2-甲氧基肉桂醛、肉桂醛和 2-羟基肉桂醛为姜黄素中的主要有效化合物。PPI 网络分析显示 PTGS2、MMP9 和 TLR4 是相关性最高的靶点。GO 和 KEGG 分析表明，姜黄素通过多种生物学过程发挥其在强直性脊柱炎中的治疗作用，包括对激素和肽的反应、氧化应激反应和炎症反应。涉及的主要信号通路包括 IL-17、TNF、NF-kappa B 和 Toll 样受体通路。分子对接分析证实了关键化合物与核心靶点之间的强亲和力。此外，免疫组织化学分析表明，强直性脊柱炎中 PTGS2、MMP9 和 TLR4 水平上调。
本研究深入了解了姜黄素治疗强直性脊柱炎的有效化合物、核心靶点和潜在作用机制。这些发现为该领域的未来基础研究奠定了坚实的基础。
